arrow-down arrow-left arrow-right check clock edit filter phone question-mark search submit-arrow

by myTomorrows myTomorrows | 23 Sep 2019

myTomorrows and Basilea Pharmaceutica International Ltd. to collaborate on Expanded Access Program

Amsterdam, Netherlands, 23 September, 2019 – myTomorrows, a Netherlands-based HealthTech company facilitating access to medicines in development and real-world data collection announces the collaboration with Basilea Pharmaceutica International Ltd., a Switzerland-based commercial-stage biopharmaceutical company focused on the development of medicinal products in the therapeutic areas of oncology and anti-infectives, to develop an Expanded Access Program (EAP) for patients with unmet needs.


Michel van Harten , MD, CMO of myTomorrows said, “I am pleased to support Basilea with their EAP. With our unique online platform, we facilitate expanded access and real-world data collection on a global scale.”.



About Expanded Access Programs


An Expanded Access Program (EAP), also known as Managed Access Program, Named Patient Supply, Autorisations temporaires d'utilisation (ATU), Compassionate Use, etc., may allow a treatment with a medicine currently not licensed in the patient’s country of residence subject to the national laws and regulations. Such treatments could be an option for patients who are in high unmet medical need and have exhausted all registered treatment options and cannot participate in a clinical trial.



About myTomorrows


myTomorrows operates as a two-sided platform. It serves the interests of both patients and HCPs, as well as drug development. On one side, the company provides information on all treatment options to patients and physicians when registered treatments have been exhausted. On the other side, myTomorrows is specialized in expanded access regulations and administration and real-world data collection, evolving scientific clinical development. myTomorrows has gained experience in running over 20 EAPs over the past 5 years, in more than 30 countries across 5 continents. For more information, please visit


For inquiries about myTomorrows or Expanded Access, please contact our medical team via